Diabetic Kidney Disease (DKD
Conditions
Interventions
Trial Group 1: Low-dose Tangshen + Standard Western Treatment:Low-dose: 1 bag each time, three times daily
Trial Group 2: Standard-dose Tangshen + Standard Western Treatment:Standard-dose: 2 bags each time, three times daily
Trial Group 3: High-dose Tangshen + Standard Western Treatment:High-dose: 3 bags each time, three times daily
Sponsors
China-Japan Friendship Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75, any gender; 2. Confirmed diagnosis of type 2 diabetes with HbA1c =30 mg/g, or eGFR 25-3 months); 4. TCM pattern of Qi-Yin deficiency with blood stasis; 5. Willing to sign informed consent and comply with follow-up.
Exclusion criteria
Exclusion criteria: 1. Severe diabetic complications (e.g., ketoacidosis, hyperosmolar coma) or recent (2×ULN); 7. Uncontrolled hypertension (resting SBP >=160 mmHg and/or DBP >=100 mmHg); 8. Psychiatric disorders affecting compliance; 9. Non-diabetic kidney disease (e.g., glomerulonephritis); 10. Hyperkalemia (serum K+ >5.5 mmol/L).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in estimated glomerular filtration rate (eGFR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in urinary albumin-to-creatinine ratio (UACR);Change from baseline in body weight, waist circumference, blood pressure, lipid profile, and glycated hemoglobin at Week 24;Change from baseline in traditional Chinese medicine syndrome score;Change from baseline in health-related quality of life (HRQoL) score; | — |
Countries
China
Contacts
Public ContactJiang Li
China-Japan friendship hospital
Outcome results
None listed